Needham Reiterates Avadel Pharmaceuticals plc - ADR (AVDL) Buy Recommendation
Nasdaq Fintel reports that on May 30, 2023, Needham reiterated coverage of Avadel Pharmaceuticals plc - ADR (NASDAQ:AVDL) with a Buy recommendation.
Analyst Price Forecast Suggests 21.24% Upside
As of May 11, 2023, the average one-year price target for Avadel Pharmaceuticals plc - ADR is 16.78. The forecasts range from a low of 7.07 to a high of $27.30. The average price target represents an increase of 21.24% from its latest reported closing price of 13.84.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Avadel Pharmaceuticals plc - ADR is 23MM, an increase of %. The projected annual non-GAAP EPS is -1.08.
What is the Fund Sentiment?
There are 113 funds or institutions reporting positions in Avadel Pharmaceuticals plc - ADR. This is an increase of 10 owner(s) or 9.71% in the last quarter. Average portfolio weight of all funds dedicated to AVDL is 0.36%, an increase of 48.92%. Total shares owned by institutions increased in the last three months by 44.68% to 48,828K shares. The put/call ratio of AVDL is 0.22, indicating a bullish outlook.